SEATTLE--(BUSINESS WIRE)--CG Therapeutics, a biotechnology company developing new cancer immunotherapies, announced today that it has entered into an agreement with the University of Washington to undertake a joint monoclonal antibody development program. CG Therapeutics is commercializing CG201, a proprietary vaccine that produces antibodies that neutralize hCG, a powerful hormone produced by tumor cell to speed their growth. The new, joint program will develop human monoclonal antibodies against hCG that can be used with the CG201 vaccine to provide a comprehensive cancer treatment.
